Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06664775 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery
A Phase 3 study of Hemorrhage, sponsored by Corza Medical.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 116
- Enrollment target
- 9
- Study locations
NCT06664775 is a Phase 3 study of Hemorrhage that is actively recruiting participants, run by Corza Medical. The registered enrollment target is 116 participants, below the 261-participant average among 20 other Hemorrhage trials with a reported enrollment target (56% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT06664775, a Phase 3 study of Hemorrhage, is actively recruiting participants, sponsored by Corza Medical.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 116 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this clinical study is to assess the efficacy and safety of TachoSil compared to the widely known and used for \> 60 years local hemostatic product Surgicel Original as an adjunct to control mild to moderate soft tissue bleeding during surgery.
Conditions Studied
Interventions
- BIOLOGICAL TachoSil
- BIOLOGICAL Surgicel Original
Study Locations (9)
California
- Torrance Memorial - Torrance
Colorado
- St. Anthony Hospital - Lakewood
District of Columbia
- Georgetown University - Washington D.C.
Illinois
- University Of Chicago - Chicago
Indiana
- Indiana University - Indianapolis
Kentucky
- University of Louisville - Louisville
Missouri
- Washington University - St Louis
North Carolina
- Atrium Health Carolinas Medical Center - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2025-04-02 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06664775
The ClinicalTrials.gov registry entry for NCT06664775 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 20 other Hemorrhage trials with a reported enrollment target (56% lower). The listed sponsor is Corza Medical, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which TachoSil is the first listed.
NCT06664775 reports 9 study locations spanning 9 distinct geographic areas - top geographies include California, Colorado, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06664775 about?
NCT06664775 is a clinical study titled "A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery". The purpose of this clinical study is to assess the efficacy and safety of TachoSil compared to the widely known and used for \> 60 years local hemostatic product Surgicel Original as an adjunct to control mild to moderate soft tissue bleeding during surgery.
What is the current status of trial NCT06664775?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 116 participants. The study started on 2025-04-02. Estimated completion is 2026-06-30.
What conditions does trial NCT06664775 study?
This clinical trial studies the following conditions: Hemorrhage.
What interventions are being tested in trial NCT06664775?
The interventions under investigation include: TachoSil (BIOLOGICAL), Surgicel Original (BIOLOGICAL).
Who is sponsoring clinical trial NCT06664775?
This trial is sponsored by Corza Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06664775 being conducted?
This trial has 9 study locations across California, Colorado, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery
COMPLETED · Phase 3
-
Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)
COMPLETED · Phase 3
-
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
RECRUITING · Phase 2
-
Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation
RECRUITING · Phase 2
-
NIRS Monitoring in Premature Infants
RECRUITING
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.